A$3.4 billion including debt—about $2.4 billion—would value I-MED in a deal Jardine Matheson is close to signing, people familiar with the matter said.
Permira, I-MED’s private equity owner, and Jardine are finalizing transaction details, with an announcement possible as soon as Monday.
I-MED would bring Australia’s largest medical diagnostic imaging provider into Jardine’s portfolio, expanding the conglomerate’s healthcare exposure.
As a conglomerate takes over I-MED, will Australian patients face higher costs for essential medical scans?
Is Jardine's A$3.4B healthcare bet a strategic masterstroke or a high-stakes gamble for a non-specialist?